Medicare will save approximately 44%, on 15 high-cost medications as a result of the second round of the program’s drug price ...

CMS announced a 44% net savings on 15 high-cost drugs under Medicare, effective January 2027, as part of the Inflation ...

Pharma companies are facing pricing pressure from several directions, including from the U.S. Medicare negotiations ...

U.S. Medicare price cuts of up to 85% will have a lesser impact on drugmakers than initially feared, with most of the hit ...

The United States has revealed price reductions for the second round of | The U.S. has revealed price reductions for the ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

The Trump administration late Tuesday announced new lower Medicare prices for 15 drugs that were part of the latest round of the program’s price negotiations, touting a total of $12 billion ...

Price are falling sharply for Medicare beneficiaries prescribed Novo Nordisk’s GLP-1 drugs like Ozempic in 2027.

The Food and Drug Administration is set to treat application under its priority program that seeks to accelerate the review ...

Novo Nordisk shares rose 5% on Wednesday after analysts said that U.S. price cuts for the Danish drugmaker's semaglutide came in broadly as expected.

On a more positive note, Novo Nordisk reported positive results from a Phase 2 trial of its next highly promising GLP-1 ...

Novo Nordisk reported promising mid-stage results for its experimental obesity drug amycretin in diabetes patients on Tuesday ...